GeneFerm Biotechnology (Taiwan) Price Prediction

1796 Stock  TWD 49.95  0.45  0.89%   
As of today, the value of RSI of GeneFerm Biotechnology's share price is approaching 43. This suggests that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling GeneFerm Biotechnology, making its price go up or down.

Oversold Vs Overbought

43

 
Oversold
 
Overbought
The successful prediction of GeneFerm Biotechnology's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of GeneFerm Biotechnology and does not consider all of the tangible or intangible factors available from GeneFerm Biotechnology's fundamental data. We analyze noise-free headlines and recent hype associated with GeneFerm Biotechnology Co, which may create opportunities for some arbitrage if properly timed.
Using GeneFerm Biotechnology hype-based prediction, you can estimate the value of GeneFerm Biotechnology Co from the perspective of GeneFerm Biotechnology response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in GeneFerm Biotechnology to buy its stock at a price that has no basis in reality. In that case, they are not buying GeneFerm because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

GeneFerm Biotechnology after-hype prediction price

    
  TWD 49.95  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out GeneFerm Biotechnology Basic Forecasting Models to cross-verify your projections.
Intrinsic
Valuation
LowRealHigh
39.4641.2754.95
Details
Naive
Forecast
LowNextHigh
49.5551.3553.16
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
46.9648.8250.67
Details

GeneFerm Biotechnology After-Hype Price Prediction Density Analysis

As far as predicting the price of GeneFerm Biotechnology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in GeneFerm Biotechnology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of GeneFerm Biotechnology, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

GeneFerm Biotechnology Estimiated After-Hype Price Volatility

In the context of predicting GeneFerm Biotechnology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on GeneFerm Biotechnology's historical news coverage. GeneFerm Biotechnology's after-hype downside and upside margins for the prediction period are 48.14 and 51.76, respectively. We have considered GeneFerm Biotechnology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
49.95
49.95
After-hype Price
51.76
Upside
GeneFerm Biotechnology is very steady at this time. Analysis and calculation of next after-hype price of GeneFerm Biotechnology is based on 3 months time horizon.

GeneFerm Biotechnology Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as GeneFerm Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GeneFerm Biotechnology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with GeneFerm Biotechnology, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.05 
1.79
 0.00  
 0.00  
0 Events / Month
0 Events / Month
In 5 to 10 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
49.95
49.95
0.00 
0.00  
Notes

GeneFerm Biotechnology Hype Timeline

GeneFerm Biotechnology is presently traded for 49.95on Taiwan OTC Exchange of Taiwan. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. GeneFerm is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is presently at 0.05%. %. The volatility of related hype on GeneFerm Biotechnology is about 0.0%, with the expected price after the next announcement by competition of 49.95. About 57.0% of the company shares are owned by insiders or employees . The book value of GeneFerm Biotechnology was presently reported as 19.63. The company last dividend was issued on the 23rd of June 2022. Assuming the 90 days trading horizon the next anticipated press release will be in 5 to 10 days.
Check out GeneFerm Biotechnology Basic Forecasting Models to cross-verify your projections.

GeneFerm Biotechnology Related Hype Analysis

Having access to credible news sources related to GeneFerm Biotechnology's direct competition is more important than ever and may enhance your ability to predict GeneFerm Biotechnology's future price movements. Getting to know how GeneFerm Biotechnology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how GeneFerm Biotechnology may potentially react to the hype associated with one of its peers.

GeneFerm Biotechnology Additional Predictive Modules

Most predictive techniques to examine GeneFerm price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for GeneFerm using various technical indicators. When you analyze GeneFerm charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About GeneFerm Biotechnology Predictive Indicators

The successful prediction of GeneFerm Biotechnology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as GeneFerm Biotechnology Co, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of GeneFerm Biotechnology based on analysis of GeneFerm Biotechnology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to GeneFerm Biotechnology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to GeneFerm Biotechnology's related companies.

Story Coverage note for GeneFerm Biotechnology

The number of cover stories for GeneFerm Biotechnology depends on current market conditions and GeneFerm Biotechnology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that GeneFerm Biotechnology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about GeneFerm Biotechnology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Other Macroaxis Stories

Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios

GeneFerm Biotechnology Short Properties

GeneFerm Biotechnology's future price predictability will typically decrease when GeneFerm Biotechnology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of GeneFerm Biotechnology Co often depends not only on the future outlook of the potential GeneFerm Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GeneFerm Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding40.8 M

Additional Tools for GeneFerm Stock Analysis

When running GeneFerm Biotechnology's price analysis, check to measure GeneFerm Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneFerm Biotechnology is operating at the current time. Most of GeneFerm Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneFerm Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneFerm Biotechnology's price. Additionally, you may evaluate how the addition of GeneFerm Biotechnology to your portfolios can decrease your overall portfolio volatility.